Skip to content

Role of the Sympathetic Nervous System in Rosacea

Role of the Sympathetic Nervous System in Rosacea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03989492
Enrollment
40
Registered
2019-06-18
Start date
2019-05-24
Completion date
2020-08-06
Last updated
2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Keywords

autonomic nervous system, skin blood flow, skin sympathetic nerve activity

Brief summary

Rosacea is a common skin disorder which causes facial redness and inflammation in about 16 million Americans, from an unknown cause. Many triggers of rosacea symptoms are stressors that affect the sympathetic (fight or flight) portion of the nervous system, and a recent pilot study suggests there is sympathetic dysfunction in rosacea. This project will benefit patients, clinicians, and basic scientists by increasing our understanding of sympathetic nervous system involvement in rosacea symptoms in order to develop improved treatments for patients with rosacea.

Interventions

OTHERsystemic and local stressors

Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
CollaboratorNIH
Kristen Metzler-Wilson
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Otherwise healthy males and non-pregnant/non-lactating females with mild to moderate erythematotelangiectactic rosacea, as well as age-sex matched healthy control subjects.

Exclusion criteria

* Neurological, cardiovascular, respiratory, metabolic, muscular, or other dermatological disorders * Current history of alcohol and/or drug abuse * Known allergies or hypersensitivities to medications/drugs that are used in the protocol * Current smoking or regular smoking within the last 2 years * Body mass index \> 35 kg/m2 * Medications or supplements which are known to affect neural, cardiovascular, or muscular responses

Design outcomes

Primary

MeasureTime frameDescription
Skin blood flowImmediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.laser Doppler flowmetry
Skin sympathetic nerve activityImmediate (during the single-day study). This study consists of a one-day protocol, during which this outcome is measured.microneurography

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026